Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting HYAL4
- Development stage
- Preclinical
- Lead developer
- University of Miami
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siRNA targeting HYAL4 is a small interfering RNA designed to silence the expression of the hyaluronidase 4 (HYAL4) gene. HYAL4 is a member of the hyaluronidase family that degrades hyaluronic acid and has been identified as a tumor-derived enzyme specifically elevated in bladder cancer tissues and urine. In preclinical research, the use of siRNA to downregulate HYAL4 expression in bladder cancer cell lines (such as HT1376 and HT5637) has demonstrated a significant decrease in cell proliferation and an induction of apoptosis. This suggests that HYAL4 plays a role in tumor progression and could serve as both a diagnostic marker and a therapeutic target for bladder cancer.
- Other names
- HYAL4 siRNAHYAL-4 siRNAHYAL 4 siRNAsiRNA-HYAL4siRNA-HYAL-4siRNA-HYAL 4
02
Targets
HYAL (Hyaluronidase family (HYAL))
Beyond the preview
Go deeper on siRNA targeting HYAL4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting HYAL4.